NAGE - NASDAQ
NB
Niagen Bioscience Inc
NAGE·NASDAQ
$3.50
-1.1%HealthcareBiotechnology
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
At a Glance
Live SnapshotMarket Cap$278.76M
EPS0.2200
P/E Ratio15.91
Earnings Date08/05/2026
nage
Total Liabilities
Last Annual Value
29.87M
3-Year CAGR
6%
5-Year CAGR
6%
10-Year CAGR
8%
NB
Niagen Bioscience Inc Competitors Analysis of Total Liabilities
NAGE · NASDAQ
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Niagen Bioscience Inc NASDAQ:NAGE | 29.87M | 4.1% | 2.7% | 11.8% | |
 Prothena Corporation plc NASDAQ:PRTA | 46.33M | -30.0% | -20.2% | -6.9% | |
 Akebia Therapeutics, Inc. NASDAQ:AKBA | 343.95M | 8.1% | -5.5% | 4.0% | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 22.52M | -12.6% | 12.9% | N/A | |
 Keros Therapeutics, Inc. NASDAQ:KROS | 34.89M | -2.6% | 23.6% | N/A | |
 REGENXBIO Inc. NASDAQ:RGNX | 350.30M | 10.1% | 0.0% | 41.4% | |
 Olema Pharmaceuticals, Inc. NASDAQ:OLMA | 54.87M | 33.5% | 37.0% | N/A | |
 Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | 9.91M | 13.0% | -4.2% | 3.0% | |
 KalVista Pharmaceuticals, Inc. NASDAQ:KALV | 338.09M | 148.0% | 86.9% | 59.1% | |
 Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | 122.11M | -5.8% | -2.3% | 18.1% | |
 Zevra Therapeutics, Inc. NASDAQ:ZVRA | 130.07M | 5.6% | 86.1% | 2.3% |
NB
Niagen Bioscience Inc Fair Value Envelope
NAGE · NASDAQ
Related Guides
Continue your NAGE research with focused valuation guides.
Research Paths
1
Snapshot
Start with context, operating signals, and key market metrics.
2
Value Model
Stress test fair value across bear, base, and bull assumptions.
3
Statements
Validate revenue quality, margins, and balance sheet durability.
4
Earnings Call
Read management commentary and compare it with reported outcomes.
5
Dividends
Check payout sustainability and long-term distribution behavior.
6
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.